Moderna Will Seek EU and US Authorization for COVID-19 Vaccine

Moderna said in a statement it will apply for US and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study revealed it was 94 percent effective with no safety concerns.

Moderna said in a statement it will apply for US and European emergency authorization for its COVID-19 vaccine on Monday after full results from a late-stage study revealed it was 94 percent effective with no safety concerns.

The company also reported that the vaccine’s efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100 percent success rate in preventing severe cases of a disease that has killed nearly 1.5 million people.

“We believe that we have a vaccine that is very highly efficacious. We now have the data to prove it. We expect to be playing a major part in turning around this pandemic,” Moderna Chief Medical Officer Tal Zaks wrote in the statement.

Of the 196 volunteers who contracted COVID-19 in the trial with more than 30,000 people, 185 received a placebo while 11 got the vaccine. The company reported 30 severe cases – all in the placebo group – which means the vaccine was 100 percent effective in preventing severe cases.

“As the numbers of cases reported grows, confidence grows that this amazing protection will be maintained in a product that can be rolled out to protect the public,” associate professor in biomedical technology at Britain’s University of Reading Alexander Edwards told CNN Business.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.